The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody
Open accessAbstract
A large body of evidence supports an important role for calcitonin gene-related peptide (CGRP) in migraine pathophysiology. This evidence gave rise to a global effort to develop a new generation of therapeutics that inhibit the interaction of CGRP with its receptor in migraineurs. Recently, a new class of such drugs, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs), were found to be effective in reducing the frequency of migraine. The purpose of this study was to better understand how the CGRP-mAb fremanezumab (TEV-48125) modulates meningeal sensory pathways. To answer this question, we used single-unit recording to determine the effects of fremanezumab (30 mg/kg, IV) and its isotype control Ab on spontaneous and evoked activity in naive and cortical spreading depression (CSD)-sensitized trigeminovascular neurons in the spinal trigeminal nucleus of anesthetized male and female rats. The study demonstrates that, in both sexes, fremanezumab inhibited naive high-threshold (HT) neurons, but not wide-dynamic range trigeminovascular neurons, and that the inhibitory effects on the neurons were limited to their activation from the intracranial dura but not facial skin or cornea. In addition, when given sufficient time, fremanezumab prevents the activation and sensitization of HT neurons by CSD. Mechanistically, these findings suggest that HT neurons play a critical role in the initiation of the perception of headache and the development of cutaneous allodynia and central sensitization. Clinically, the findings may help to explain the therapeutic benefit of CGRP-mAb in reducing headaches of intracranial origin such as migraine with aura and why this therapeutic approach may not be effective for every migraine patient. SIGNIFICANCE STATEMENT Calcitonin gene-related peptide (CGRP) monoclonal antibodies (CGRP-mAbs) are capable of preventing migraine. However, their mechanism of action is unknown. In the current study, we show that, if given enough time, a CGRP-mAb can prevent the activation and sensitization of high-threshold (central) trigeminovascular neurons by cortical spreading depression, but not their activation from the skin or cornea, suggesting a potential explanation for selectivity to migraine headache, but not other pains, and a predominantly peripheral site of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How do you feel? Interoception: The sense of the physiological condition of the body
Craig, A. D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn894 · Cited by 6,006
Cited by
Dodick, D. W. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30478-1 · Cited by 557
CGRP and the Trigeminal System in Migraine
Iyengar, S., Johnson, K. W., Ossipov, M. H., & Aurora, S. K. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13529 · Cited by 486
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Does inflammation have a role in migraine?
Edvinsson, L., Haanes, K. A., & Warfvinge, K. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0216-y · Cited by 311
Noseda, R., Schain, A. J., Melo-Carrillo, A., Tien, J., Stratton, J., Mai, F., Strassman, A. M., & Burstein, R. (2020) · Cephalalgia · doi:10.1177/0333102419896760 · Cited by 98
Self-citation
Metadata
- Authors
- Melo-Carrillo, A., Noseda, R., Nir, R.-R., Schain, A. J., Stratton, J., Strassman, A. M., & Burstein, R.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2017-06-22
- Volume
- 37
- Issue
- 30
- Pages
- 7149-7163
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2676947678
- Cited by
- 163
- References
- 1
- FWCI
- 14.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody. https://app.cochat.ai/papers/10.1523/jneurosci.0576-17.2017
- The paper
- Melo-Carrillo, A., Noseda, R., Nir, R.-R., Schain, A. J., Stratton, J., Strassman, A. M., & Burstein, R. (2017). Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.0576-17.2017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.